Is contrast enhancement needed for diagnostic prostate MRI?

Transl Androl Urol. 2017 Jun;6(3):499-509. doi: 10.21037/tau.2017.05.31.

Abstract

Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) provides clinical guidelines for multiparametric magnetic resonance imaging (mpMRI) [T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)] of prostate. However, DCE-MRI seems to show a limited contribution in prostate cancer (PCa) detection and management. In our experience, DCE-MRI, did not show significant change in diagnostic performance in addition to DWI and T2WI [biparametric MRI (bpMRI)] which represent the predominant sequences to detect suspected lesions in peripheral and transitional zone (TZ). In this article we reviewed the role of DCE-MRI also indicating the potential contribute of bpMRI approach (T2WI and DWI) and lesion volume evaluation in the diagnosis and management of suspected PCa.

Keywords: Prostate Imaging Reporting and Data System version 2 (PI-RADS v2); Prostate cancer (PCa); biparametric magnetic resonance imaging (bpMRI).

Publication types

  • Review